MDS: Low Risk Isn't No Risk
About this episode
This episode discusses the implications of low-risk myelodysplastic syndromes and the importance of clear communication with patients.
Myelodysplastic syndromes (MDS), a rare category of bone marrow disorders that may develop into acute myeloid leukemia, are categorized into risk groups ranging from very low to very high risk. However, this language can be misleading to patients. Low risk (LR) does not equate to low impact or lack of urgency. In this episode, CANCER BUZZ speaks with Amy DeZern, MD, MHS, from Sidney Kimmel Comprehensive Cancer Center, and Christin Blair DeStefano, MD, FACP, from Walter Reed National Military Medical Center, about the importance of aligning language and terminology regarding LR-MDS across academic and community settings. These experts candidly discuss their own collaboration and the importance of early conversations with patients to align expectations on goals, disease trajectory, and treatment sequencing. Guests: Amy DeZern, MD, MHS Hematologist/Oncologist Director, Bone Marrow Failure and MDS Program Sidney Kimmel Comprehensive Cancer Center Baltimore, MD Christin Blair DeStefano, MD, FACP Hematologist/Oncologist Walter Reed National Military Medical Center Bethesda, MD "I really try and individualize [language] to a patient and their family, because I worry that sometimes the…
More episodes of CANCER BUZZ
- The Urology-Oncology Partnership in ADCs
- A Team Approach to ADCs in Bladder Cancer
- Beyond Body Art: Restoring Wholeness Through Paramedical Tattooing
- Bridging Radiation and Oncology in SCLC Care
- Championing Bispecific Antibodies in the VA
- Data-Driven Toxicity Management for ADCs
Explore listener stats, chart rankings, contacts and more on the CANCER BUZZ podcast page.